142 related articles for article (PubMed ID: 28076787)
1. IMPDH2 Is an Intracellular Target of the Cyclophilin A and Sanglifehrin A Complex.
Pua KH; Stiles DT; Sowa ME; Verdine GL
Cell Rep; 2017 Jan; 18(2):432-442. PubMed ID: 28076787
[TBL] [Abstract][Full Text] [Related]
2. Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action.
Zenke G; Strittmatter U; Fuchs S; Quesniaux VF; Brinkmann V; Schuler W; Zurini M; Enz A; Billich A; Sanglier JJ; Fehr T
J Immunol; 2001 Jun; 166(12):7165-71. PubMed ID: 11390463
[TBL] [Abstract][Full Text] [Related]
3. Sanglifehrin-cyclophilin interaction: degradation work, synthetic macrocyclic analogues, X-ray crystal structure, and binding data.
Sedrani R; Kallen J; Martin Cabrejas LM; Papageorgiou CD; Senia F; Rohrbach S; Wagner D; Thai B; Jutzi Eme AM; France J; Oberer L; Rihs G; Zenke G; Wagner J
J Am Chem Soc; 2003 Apr; 125(13):3849-59. PubMed ID: 12656618
[TBL] [Abstract][Full Text] [Related]
4. Sanglifehrin A, a novel cyclophilin-binding immunosuppressant, inhibits IL-2-dependent T cell proliferation at the G1 phase of the cell cycle.
Zhang LH; Liu JO
J Immunol; 2001 May; 166(9):5611-8. PubMed ID: 11313401
[TBL] [Abstract][Full Text] [Related]
5. Enantioselective Synthesis and Biological Evaluation of Sanglifehrin A and B and Analogs.
Chang CF; Flaxman HA; Woo CM
Angew Chem Int Ed Engl; 2021 Jul; 60(31):17045-17052. PubMed ID: 34014025
[TBL] [Abstract][Full Text] [Related]
6. Highly selective inhibition of IMPDH2 provides the basis of antineuroinflammation therapy.
Liao LX; Song XM; Wang LC; Lv HN; Chen JF; Liu D; Fu G; Zhao MB; Jiang Y; Zeng KW; Tu PF
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5986-E5994. PubMed ID: 28674004
[TBL] [Abstract][Full Text] [Related]
7. ANKRD9 is a metabolically-controlled regulator of IMPDH2 abundance and macro-assembly.
Hayward D; Kouznetsova VL; Pierson HE; Hasan NM; Guzman ER; Tsigelny IF; Lutsenko S
J Biol Chem; 2019 Sep; 294(39):14454-14466. PubMed ID: 31337707
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of derivatives of the novel cyclophilin-binding immunosuppressant sanglifehrin A with reduced numbers of polar functions.
Bänteli R; Wagner J; Zenke G
Bioorg Med Chem Lett; 2001 Jun; 11(12):1609-12. PubMed ID: 11412991
[TBL] [Abstract][Full Text] [Related]
9. Cyclophilin sensitivity to sanglifehrin A can be correlated to the same specific tryptophan residue as cyclosporin A.
Pemberton TJ; Kay JE
FEBS Lett; 2003 Dec; 555(2):335-40. PubMed ID: 14644438
[TBL] [Abstract][Full Text] [Related]
10. Structure of human cyclophilin A in complex with the novel immunosuppressant sanglifehrin A at 1.6 A resolution.
Kallen J; Sedrani R; Zenke G; Wagner J
J Biol Chem; 2005 Jun; 280(23):21965-71. PubMed ID: 15772070
[TBL] [Abstract][Full Text] [Related]
11. Cloning, sequencing and characterization of the biosynthetic gene cluster of sanglifehrin A, a potent cyclophilin inhibitor.
Qu X; Jiang N; Xu F; Shao L; Tang G; Wilkinson B; Liu W
Mol Biosyst; 2011 Mar; 7(3):852-61. PubMed ID: 21416665
[TBL] [Abstract][Full Text] [Related]
12. Silencing of hepsin and inosine 5-monophosphate dehydrogenase 2 by siRNA reduces prostate cancer cells proliferation.
A Wahab N; D Dardar H; Yunus R; M Zainudin Z; M Mokhtar N
Malays J Pathol; 2022 Apr; 44(1):29-38. PubMed ID: 35484884
[TBL] [Abstract][Full Text] [Related]
13. Assembly of IMPDH2-based, CTPS-based, and mixed rod/ring structures is dependent on cell type and conditions of induction.
Keppeke GD; Calise SJ; Chan EK; Andrade LE
J Genet Genomics; 2015 Jun; 42(6):287-99. PubMed ID: 26165495
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics.
Wu TY; Peng Y; Pelleymounter LL; Moon I; Eckloff BW; Wieben ED; Yee VC; Weinshilboum RM
Br J Pharmacol; 2010 Dec; 161(7):1584-98. PubMed ID: 20718729
[TBL] [Abstract][Full Text] [Related]
15. Ultrastructure of cytoplasmic and nuclear inosine-5'-monophosphate dehydrogenase 2 "rods and rings" inclusions.
Juda P; Smigová J; Kováčik L; Bártová E; Raška I
J Histochem Cytochem; 2014 Oct; 62(10):739-50. PubMed ID: 24980853
[TBL] [Abstract][Full Text] [Related]
16. A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity.
Wang J; Zeevi A; Webber S; Girnita DM; Addonizio L; Selby R; Hutchinson IV; Burckart GJ
Pharmacogenet Genomics; 2007 Apr; 17(4):283-90. PubMed ID: 17496727
[TBL] [Abstract][Full Text] [Related]
17. Different characteristics and nucleotide binding properties of inosine monophosphate dehydrogenase (IMPDH) isoforms.
Thomas EC; Gunter JH; Webster JA; Schieber NL; Oorschot V; Parton RG; Whitehead JP
PLoS One; 2012; 7(12):e51096. PubMed ID: 23236438
[TBL] [Abstract][Full Text] [Related]
18. Mycobacterium tuberculosis IMPDH in Complexes with Substrates, Products and Antitubercular Compounds.
Makowska-Grzyska M; Kim Y; Gorla SK; Wei Y; Mandapati K; Zhang M; Maltseva N; Modi G; Boshoff HI; Gu M; Aldrich C; Cuny GD; Hedstrom L; Joachimiak A
PLoS One; 2015; 10(10):e0138976. PubMed ID: 26440283
[TBL] [Abstract][Full Text] [Related]
19. Development of a recombinant cell-based indirect immunofluorescence assay (RC-IFA) for the determination of autoantibodies against "rings and rods"-associated inosine-5'-monophosphate dehydrogenase 2 in viral hepatitis C.
Probst C; Radzimski C; Blöcker IM; Teegen B; Bogdanos DP; Stöcker W; Komorowski L
Clin Chim Acta; 2013 Mar; 418():91-6. PubMed ID: 23333419
[TBL] [Abstract][Full Text] [Related]
20. Berberrubine is a novel and selective IMPDH2 inhibitor that impairs the growth of colorectal cancer.
He X; Cui J; Ma H; Abuduaini N; Huang Y; Tang L; Wang W; Zhang Y; Wang Y; Lu W; Feng B; Huang J
Biochem Pharmacol; 2023 Dec; 218():115868. PubMed ID: 37871880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
